143 related articles for article (PubMed ID: 37145970)
1. Dexmedetomidine Pretreatment Protects Against Myocardial Ischemia/Reperfusion Injury by Activating STAT3 Signaling.
Chen ZR; Hong Y; Wen SH; Zhan YQ; Huang WQ
Anesth Analg; 2023 Aug; 137(2):426-439. PubMed ID: 37145970
[TBL] [Abstract][Full Text] [Related]
2. Dexmedetomidine pretreatment protects the heart against apoptosis in ischemia/reperfusion injury in diabetic rats by activating PI3K/Akt signaling in vivo and in vitro.
Chang JH; Jin MM; Liu JT
Biomed Pharmacother; 2020 Jul; 127():110188. PubMed ID: 32407987
[TBL] [Abstract][Full Text] [Related]
3. Effects of dexmedetomidine on myocardial ischemia-reperfusion injury through PI3K-Akt-mTOR signaling pathway.
Zhang J; Jiang H; Liu DH; Wang GN
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6736-6743. PubMed ID: 31378917
[TBL] [Abstract][Full Text] [Related]
4. Dexmedetomidine Attenuates Myocardial Ischemia-Reperfusion Injury in Diabetes Mellitus by Inhibiting Endoplasmic Reticulum Stress.
Li J; Zhao Y; Zhou N; Li L; Li K
J Diabetes Res; 2019; 2019():7869318. PubMed ID: 31886285
[TBL] [Abstract][Full Text] [Related]
5. Effects of dexmedetomidine postconditioning on myocardial ischemia and the role of the PI3K/Akt-dependent signaling pathway in reperfusion injury.
Cheng XY; Gu XY; Gao Q; Zong QF; Li XH; Zhang Y
Mol Med Rep; 2016 Jul; 14(1):797-803. PubMed ID: 27221008
[TBL] [Abstract][Full Text] [Related]
6. Dexmedetomidine-induced cardioprotection is mediated by inhibition of high mobility group box-1 and the cholinergic anti-inflammatory pathway in myocardial ischemia-reperfusion injury.
Zhang J; Xia F; Zhao H; Peng K; Liu H; Meng X; Chen C; Ji F
PLoS One; 2019; 14(7):e0218726. PubMed ID: 31344138
[TBL] [Abstract][Full Text] [Related]
7. Dexmedetomidine protects cardiomyocytes against hypoxia/reoxygenation injury via multiple mechanisms.
Cai S; Liu Y; Cheng Y; Yuan J; Fang J
J Clin Lab Anal; 2022 Jul; 36(7):e24119. PubMed ID: 34882841
[TBL] [Abstract][Full Text] [Related]
8. Dexmedetomidine post-treatment attenuates cardiac ischaemia/reperfusion injury by inhibiting apoptosis through HIF-1α signalling.
Peng K; Chen WR; Xia F; Liu H; Meng XW; Zhang J; Liu HY; Xia ZY; Ji FH
J Cell Mol Med; 2020 Jan; 24(1):850-861. PubMed ID: 31680420
[TBL] [Abstract][Full Text] [Related]
9. Dexmedetomidine Preconditioning Attenuates Myocardial Ischemia/Reperfusion Injury in Rats by Suppressing Mitophagy Via Activating Α2-Adrenergic Receptor.
Chen Y; Chen H; Chen Y; Yang Z; Zhou T; Xu W
Arq Bras Cardiol; 2023 Oct; 120(10):e20220750. PubMed ID: 37909577
[TBL] [Abstract][Full Text] [Related]
10. Dexmedetomidine protects the heart against ischemia reperfusion injury via regulation of the bradykinin receptors.
Song J; Du J; Tan X; Wu Z; Yuan J; Cong B
Eur J Pharmacol; 2021 Nov; 911():174493. PubMed ID: 34506777
[TBL] [Abstract][Full Text] [Related]
11. Dexmedetomidine reduces myocardial ischemia-reperfusion injury in young mice through MIF/AMPK/GLUT4 axis.
Chen S; Li A; Wu J; Huang Y; Zou T; Tailaiti T; Wang J
BMC Anesthesiol; 2022 Sep; 22(1):289. PubMed ID: 36104681
[TBL] [Abstract][Full Text] [Related]
12. Dexmedetomidine postconditioning attenuates myocardial ischemia/reperfusion injury by activating the Nrf2/Sirt3/SOD2 signaling pathway in the rats.
Hu B; Tian T; Li XT; Hao PP; Liu WC; Chen YG; Jiang TY; Chen PS; Cheng Y; Xue FS
Redox Rep; 2023 Dec; 28(1):2158526. PubMed ID: 36738240
[TBL] [Abstract][Full Text] [Related]
13. Dexmedetomidine Protects against Myocardial Ischemia/Reperfusion Injury by Ameliorating Oxidative Stress and Cell Apoptosis through the Trx1-Dependent Akt Pathway.
Wu ZL; Davis JRJ; Zhu Y
Biomed Res Int; 2020; 2020():8979270. PubMed ID: 33299886
[TBL] [Abstract][Full Text] [Related]
14. Dexmedetomidine inhibits pyroptosis by down-regulating miR-29b in myocardial ischemia reperfusion injury in rats.
Zhong Y; Li YP; Yin YQ; Hu BL; Gao H
Int Immunopharmacol; 2020 Sep; 86():106768. PubMed ID: 32679539
[TBL] [Abstract][Full Text] [Related]
15. The cardioprotective effect of dexmedetomidine on regional ischemia/reperfusion injury in type 2 diabetic rat hearts.
Deng L; Chen H; Wei N; Zhang Z; Wang G
Microvasc Res; 2019 May; 123():1-6. PubMed ID: 30179598
[TBL] [Abstract][Full Text] [Related]
16. Dexmedetomidine Preconditioning Reduces Myocardial Ischemia-Reperfusion Injury in Rats by Inhibiting the PERK Pathway.
Chen Y; Cao S; Chen H; Yin C; Xu X; Yang Z
Arq Bras Cardiol; 2021 Dec; 117(6):1134-1144. PubMed ID: 34644786
[TBL] [Abstract][Full Text] [Related]
17. Dexmedetomidine alleviates myocardial ischemia-reperfusion injury by down-regulating miR-34b-3p to activate the Jagged1/Notch signaling pathway.
Guo P; Yi H; Han M; Liu X; Chen K; Qing J; Yang F
Int Immunopharmacol; 2023 Mar; 116():109766. PubMed ID: 36764271
[TBL] [Abstract][Full Text] [Related]
18. Aucubin protects against myocardial ischemia-reperfusion injury by regulating STAT3/NF-κB/HMGB-1 pathway.
Liu Y; Cheng X; Qi B; Wang Y; Zheng Y; Liang X; Chang Y; Ning M; Gao W; Li T
Int J Cardiol; 2024 Apr; 400():131800. PubMed ID: 38244891
[TBL] [Abstract][Full Text] [Related]
19. Dexmedetomidine Ameliorates Cardiac Ischemia/Reperfusion Injury by Enhancing Autophagy Through Activation of the AMPK/SIRT3 Pathway.
He H; Liu P; Li P
Drug Des Devel Ther; 2023; 17():3205-3218. PubMed ID: 37908314
[TBL] [Abstract][Full Text] [Related]
20. The Protective Mechanism of Dexmedetomidine in Regulating Atg14L-Beclin1-Vps34 Complex Against Myocardial Ischemia-Reperfusion Injury.
Li Y; Qu M; Xing F; Li H; Cheng D; Xing N; Zhang W
J Cardiovasc Transl Res; 2021 Dec; 14(6):1063-1074. PubMed ID: 33914271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
